SCHEDULE: Deerfield Discloses 5.8% Stake in BioCryst Pharma
Beneficial Ownership Disclosure (Schedule 13G)
Deerfield Management and its affiliates have disclosed a 5.80% beneficial ownership stake in BioCryst Pharmaceuticals, Inc., totaling 12,169,000 common shares.
Summary
- Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn collectively reported beneficial ownership of 12,169,000 shares of BioCryst Pharmaceuticals, Inc. Common Stock.
- This aggregate ownership represents 5.80% of the issuer's outstanding Common Stock.
- The reporting persons share both voting and dispositive power over all 12,169,000 beneficially owned shares.
- The shares were not acquired for the purpose of changing or influencing the control of BioCryst Pharmaceuticals, Inc., nor in connection with any transaction having such purpose or effect, other than activities solely related to a nomination under SEC rules.
- The filing was made on September 19, 2025, reporting an event that occurred on September 12, 2025.
Sentiment
Score: 7
Explanation: The disclosure of a significant institutional stake is generally a positive signal, indicating investor confidence, although it is a passive filing and not an active investment announcement by the company.
Positives
- The disclosure of a significant 5.80% stake by a prominent institutional investor like Deerfield Management can be viewed as a vote of confidence in BioCryst Pharmaceuticals, Inc.'s long-term prospects.
- Increased institutional ownership may contribute to greater stability in the company's shareholder base.
Industry Context
This filing reflects a significant investment by a healthcare-focused institutional investor in a biotechnology company, a common occurrence in the sector as funds take positions in promising pharmaceutical firms.
Stakeholder Impact
- Shareholders: Increased institutional ownership may provide greater stability to the shareholder base and potentially signal confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 09/12/2025 | Date of event which required the filing of this statement (acquisition of 5% beneficial ownership). |
| 09/19/2025 | Date the Schedule 13G filing was signed and submitted to the SEC. |
Keywords
BioCryst Pharmaceuticals, Deerfield Management, Institutional Ownership, Schedule 13G, Common Stock, Biotechnology, Pharmaceuticals, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.